サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1226895

中東・アフリカの肺動脈性肺高血圧症市場、2028年までの予測-地域別分析-薬剤別、タイプ別、投与経路別、流通チャネル別

Middle East & Africa Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel
出版日: | 発行: The Insight Partners | ページ情報: 英文 134 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
中東・アフリカの肺動脈性肺高血圧症市場、2028年までの予測-地域別分析-薬剤別、タイプ別、投与経路別、流通チャネル別
出版日: 2023年02月14日
発行: The Insight Partners
ページ情報: 英文 134 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中東・アフリカの肺動脈性肺高血圧症市場は、2022年の4億1,088万米ドルから2028年には5億3,574万米ドルに成長すると予測され、2022年から2028年までのCAGRは4.5%と推定されています。

予測期間中、中東・アフリカ肺動脈性肺高血圧症市場の成長に有利な機会を提供する特許失効の拡大

特許の失効により、ジェネリック医薬品が市場に参入し、製品ラインアップが多様化します。今後数年間で、いくつかの特許製品が特許切れとなることが予想され、ジェネリック製剤企業にとって大きなチャンスとなる可能性が高いです。finds Care Ratingsなど多くの製薬会社は、すでに特許製品のジェネリック版の開発に取り組んでいます。特許が切れた後、ジェネリック医薬品が利用できるようになります。消費者が低価格の恩恵を受ける一方で、特許保護を失うと、製薬会社は競争の激化にさらされることになります。したがって、特許失効は、ジェネリック医薬品メーカーが新たな市場に参入する機会を提供するものと期待されます。したがって、特許失効の拡大は、今後数年間、中東・アフリカの肺動脈性肺高血圧症市場の成長に有利な機会を提供すると予想されます。

中東・アフリカの肺動脈性肺高血圧症市場の概要

中東・アフリカの肺動脈性肺高血圧症市場は、UAE、サウジアラビア、南アフリカ、その他中東・アフリカに区分されます。サウジアラビアは、予測期間中（2022年から2028年まで）、最大の市場シェアを占めると予想されます。サウジアラビアは、肺動脈性肺高血圧症市場のかなりの成長を記録すると推定されます。サウジアラビアは中東最大の経済大国であり、国全体で様々な研究開発プログラムの成長に秀でています。同国は医薬品製造の分野でも有名になりつつあります。さらに、サウジアラビアは、さまざまな規制や同国におけるPAH治療薬の高い需要により、中東・アフリカの肺動脈性肺高血圧症市場にプラスの影響を与えると予想されています。さらに、いくつかの団体が、サウジアラビアの人々の間でPAHに関する認識と知識を高めています。例えば、Saudi Association for Pulmonary Hypertension（SAPH）は、サウジアラビアの人々の認識と医療従事者の肺血管疾患に関する知識を高めるために活動しています。さらに、サウジアラビア政府は、石油依存度を下げ、ヘルスケアを含む他の分野を多様化するために「サウジ・ビジョン2030」プログラムを立ち上げ、ヘルスケアサービスの著しい発展や高度医療技術の高い導入率につながっています。ビジョン2030」のもと、サウジアラビア政府は、医薬品や医療機器の現地生産を優先し、国内のヘルスケアインフラを整備するために650億米ドル以上の投資を計画しています。このように、PAHに対する意識の高まりとサウジ・ビジョン2030の始動により、今後数年間、中東・アフリカのサウジアラビアにおける肺動脈性肺高血圧症市場の成長が促進されると予想されます。

中東・アフリカ肺動脈性肺高血圧症市場の収益と2028年までの予測（金額）

中東・アフリカの肺動脈性肺高血圧症市場のセグメンテーション

中東・アフリカの肺動脈性肺高血圧症市場は、薬剤、タイプ、投与経路、流通チャネル、国に基づいてセグメント化されます。

薬剤に基づき、中東・アフリカの肺動脈性肺高血圧症市場は、エンドセリン受容体拮抗薬（ERA）、プロスタサイクリンおよびプロスタサイクリン類似体、sGC刺激薬、pde-5 dipsticksに区分されます。2022年、プロスタサイクリンおよびプロスタサイクリンアナログセグメントは中東・アフリカの肺動脈性肺高血圧症市場で最大のシェアを記録しました。

タイプに基づき、中東・アフリカの肺動脈性肺高血圧症市場は、ブランド品とジェネリック医薬品に二分されます。2022年、中東・アフリカの肺動脈性肺高血圧症市場では、ブランド品セグメントがより大きなシェアを記録しました。

投与経路に基づき、中東・アフリカの肺動脈性肺高血圧症市場は、経口、静脈内/皮下、吸入に区分されます。2022年、中東・アフリカの肺動脈性肺高血圧症市場では、経口投与セグメントが最大のシェアを記録しました。

流通チャネルに基づき、中東・アフリカの肺動脈性肺高血圧症市場は、病院薬局・クリニック、オンライン薬局、小売薬局に区分されます。2022年、中東・アフリカの肺動脈性肺高血圧症市場では、病院薬局・クリニック部門が最大のシェアを記録しました。

国別に見ると、中東・アフリカの肺動脈性肺高血圧症市場は、サウジアラビア、南アフリカ、UAE、その他中東・アフリカに区分されます。2022年、中東・アフリカの肺動脈性肺高血圧症市場では、サウジアラビアが最大のシェアを記録しました。

Bayer AG、Gilead Sciences Inc、GSK Plc、Johnson &Johnson、Lupin Ltd、Novartis AG、Pfizer Inc、Teva Pharmaceutical Industries Ltdは、中東・アフリカ肺動脈性肺高血圧症市場で事業を展開している主要企業です。

目次

第1章 イントロダクション

第2章 中東・アフリカ肺動脈性肺高血圧症市場- 主要な要点

第3章 調査手法

  • カバレッジ
  • 2次調査
  • 1次調査

第4章 中東・アフリカ肺動脈性肺高血圧症市場- 市場情勢

  • 中東・アフリカのPEST分析
  • 専門家の見解

第5章 中東・アフリカ肺動脈性肺高血圧症市場- 主要な市場力学

  • 市場促進要因
    • 肺動脈性肺高血圧症の罹患率の増加
  • 市場抑制要因
    • 肺動脈性肺高血圧症の治療に使用される薬剤の副作用
  • 市場機会
    • 特許切れ別ジェネリック医薬品の入手の困難化
  • 今後の動向
    • 肺動脈性肺高血圧症の治療薬開発のための臨床試験の増加
  • 影響度分析

第6章 肺動脈性肺高血圧症市場-中東・アフリカ分析

  • 中東・アフリカの肺動脈性肺高血圧症市場の収益予測と分析

第7章 中東・アフリカの肺動脈性肺高血圧症市場-2028年までの収益と予測：薬剤別

  • 中東・アフリカ肺動脈性肺高血圧症市場の売上高シェア：薬剤別2021年・2028年（%）
  • エンドセリン受容体拮抗薬（ERAs）
  • プロスタサイクリンおよびプロスタサイクリンアナログ
  • SGC刺激剤
  • Pde-5ディップスティック

第8章 中東・アフリカ肺動脈性肺高血圧症の市場分析と2028年までの予測：タイプ別

  • 中東・アフリカ肺動脈性肺高血圧症市場：タイプ別2021年・2028年（%）
  • ブランド品
  • ジェネリック医薬品

第9章 中東・アフリカ肺動脈性肺高血圧症市場-2028年までの収益と予測：投与経路別

  • 中東・アフリカ肺動脈性肺高血圧症市場の売上高シェア：投与経路別2021年・2028年（%）
  • 経口
  • 静脈内/皮下
  • 吸入投与

第10章 中東・アフリカ肺動脈性肺高血圧症市場-2028年までの収益と予測-流通チャネル別

  • 中東・アフリカ肺動脈性肺高血圧症市場売上高シェア：流通チャネル別2021年・2028年（%）
  • 病院の薬局・クリニック
  • オンライン薬局
  • 小売薬局

第11章 中東・アフリカ肺動脈性肺高血圧症市場-2028年までの収益と予測：国別分析

    • 中東・アフリカ地域
      • UAE
      • サウジアラビア
      • 南アフリカ共和国
      • その他中東・アフリカ

第12章 中東・アフリカの肺動脈性肺高血圧症市場- 業界情勢

  • 有機的な展開
  • 無機的な展開

第13章 企業プロファイル

  • Johnson & Johnson
  • Gilead Sciences Inc
  • Bayer AG
  • Novartis AG
  • GSK Plc
  • Teva Pharmaceutical Industries Ltd
  • Lupin Ltd
  • Pfizer Inc

第14章 付録

図表

List Of Tables

  • Table 1. MEA Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. UAE Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. UAE Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. UAE Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. UAE Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. Saudi Arabia Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. Saudi Arabia Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Saudi Arabia Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. Saudi Arabia Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. South Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. South Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. South Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. South Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Rest of the MEA Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Rest of the MEA Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Organic Developments in the MEA pulmonary arterial hypertension market
  • Table 19. Inorganic Developments in the MEA pulmonary arterial hypertension market
  • Table 20. Glossary of Terms

List Of Figures

  • Figure 1. MEA Pulmonary Arterial Hypertension Market Segmentation
  • Figure 2. MEA Pulmonary Arterial Hypertension Market - By Country
  • Figure 3. MEA Pulmonary Arterial Hypertension Market Overview
  • Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of the MEA Pulmonary Arterial Hypertension Market
  • Figure 5. Saudi Arabia to Show Significant Growth During Forecast Period
  • Figure 6. MEA: PEST Analysis
  • Figure 7. Experts Opinion
  • Figure 8. MEA Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
  • Figure 9. MEA Pulmonary Arterial Hypertension Market- Revenue Forecast and Analysis - 2020 - 2028
  • Figure 10. MEA Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
  • Figure 11. Endothelin Receptor Antagonists (ERAs): MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Prostacyclin and Prostacyclin Analogs: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. sGC Stimulators: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. Pde-5 Dipsticks: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 15. MEA Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
  • Figure 16. Branded: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. Generics: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. MEA Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
  • Figure 19. Oral: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Intravenous/ Subcutaneous: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Inhalational: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. MEA Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
  • Figure 23. Hospital Pharmacies and Clinics: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Online Pharmacies: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Retail Pharmacies: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 27. UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
目次
Product Code: BMIRE00028069

The Middle East & Africa pulmonary arterial hypertension market is expected to grow from US$ 410.88 million in 2022 to US$ 535.74 Million by 2028; it is estimated to grow at a CAGR of 4.5% from 2022 to 2028.

Growing Patent Expiration to Offer Lucrative Opportunities for Middle East & Africa Pulmonary Arterial Hypertension Market Growth During Forecast Period

Patent expiry permits generic drugs to enter the market and diversify product offerings. A few patented products are expected to become off-patent in the coming years, which is likely to provide an enormous opportunity for generic formulation companies. Many pharma companies such as finds Care Ratings are already working to develop the generic version of patented products. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to offer an opportunity for generic drug manufacturers to enter a new market. Hence, the growing patent expiration is expected to offer lucrative opportunities for the Middle East & Africa pulmonary arterial hypertension market growth in the coming years.

Middle East & Africa Pulmonary Arterial Hypertension Market Overview

The Middle East & Africa pulmonary arterial hypertension market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. Saudi Arabia is expected to account for the largest market share during the forecasted period i.e., from 2022 to 2028. Saudi Arabia is estimated to register considerable pulmonary arterial hypertension market growth. Saudi Arabia is the largest economy in the Middle East, excelling in the growth of various research and development programs across the nation. The country is becoming well-known in the field of pharmaceutical manufacturing. Furthermore, Saudi Arabia is expected to positively impact the Middle East & Africa pulmonary arterial hypertension market due to various regulations and the high demand for PAH drugs in the country. Additionally, several organizations are increasing awareness and knowledge about PAH among the population of Saudi Arabia. For instance, Saudi Association for Pulmonary Hypertension (SAPH) is working to increase awareness among people and knowledge of pulmonary vascular diseases among medical professionals in Saudi Arabia. Further, the government of Saudi Arabia launched the Saudi Vision 2030 program to reduce oil dependence and diversify other sectors, including healthcare, which is leading to significant development in healthcare services and a high adoption rate of advanced medical technologies. Under Vision 2030, the Saudi Arabian Government plans to invest over US$ 65 billion to develop the healthcare infrastructure in the country by prioritizing local production of pharmaceuticals and medical devices. Thus, the increasing awareness about PAH and the launch of Saudi Vision 2030 is expected to fuel the growth of the Middle East & Africa pulmonary arterial hypertension market in Saudi Arabia in the coming years.

Middle East & Africa Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)

Middle East & Africa Pulmonary Arterial Hypertension Market Segmentation

The Middle East & Africa pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the Middle East & Africa pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.

Based on type, the Middle East & Africa pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Middle East & Africa pulmonary arterial hypertension market.

Based on route of administration, the Middle East & Africa pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.

Based on distribution channel, the Middle East & Africa pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.

Based on country, the Middle East & Africa pulmonary arterial hypertension market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. In 2022, Saudi Arabia registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.

Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Middle East & Africa pulmonary arterial hypertension market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa pulmonary arterial hypertension market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the pulmonary arterial hypertension market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 MEA Pulmonary Arterial Hypertension Market - By Drugs
    • 1.3.2 MEA Pulmonary Arterial Hypertension Market - By Type
    • 1.3.3 MEA Pulmonary Arterial Hypertension Market - By Route of Administration
    • 1.3.4 MEA Pulmonary Arterial Hypertension Market - By Distribution Channel
    • 1.3.5 MEA Pulmonary Arterial Hypertension Market - By Country

2. MEA Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. MEA Pulmonary Arterial Hypertension Market - Market Landscape

  • 4.1 Overview
  • 4.2 MEA PEST Analysis
  • 4.3 Experts Opinion

5. MEA Pulmonary Arterial Hypertension Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
  • 5.2 Market Restraints
    • 5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
  • 5.3 Market Opportunities
    • 5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
  • 5.4 Future Trend
    • 5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
  • 5.5 Impact analysis

6. Pulmonary Arterial Hypertension Market - MEA Analysis

  • 6.1 MEA Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis

7. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs

  • 7.1 Overview
  • 7.2 MEA Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
  • 7.3 Endothelin Receptor Antagonists (ERAs)
    • 7.3.1 Overview
    • 7.3.2 Endothelin Receptor Antagonists (ERAs): MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Prostacyclin and Prostacyclin Analogs
    • 7.4.1 Overview
    • 7.4.2 Prostacyclin and Prostacyclin Analogs: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 SGC Stimulators
    • 7.5.1 Overview
    • 7.5.2 sGC Stimulators: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Pde-5 Dipsticks
    • 7.6.1 Overview
    • 7.6.2 Pde-5 Dipsticks: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

8. MEA Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

  • 8.1 Overview
  • 8.2 MEA Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
  • 8.3 Branded
    • 8.3.1 Overview
    • 8.3.2 Branded: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Generics
    • 8.4.1 Overview
    • 8.4.2 Generics: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

9. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

  • 9.1 Overview
  • 9.2 MEA Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
  • 9.3 Oral
    • 9.3.1 Overview
    • 9.3.2 Oral: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Intravenous/ Subcutaneous
    • 9.4.1 Overview
    • 9.4.2 Intravenous/ Subcutaneous: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Inhalational
    • 9.5.1 Overview
    • 9.5.2 Inhalational: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

10. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

  • 10.1 Overview
  • 10.2 MEA Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
  • 10.3 Hospital Pharmacies and Clinics
    • 10.3.1 Overview
    • 10.3.2 Hospital Pharmacies and Clinics: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.4 Online Pharmacies
    • 10.4.1 Overview
    • 10.4.2 Online Pharmacies: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.5 Retail Pharmacies
    • 10.5.1 Overview
    • 10.5.2 Retail Pharmacies: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

11. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Country Analysis

  • 11.1 Overview
    • 11.1.1 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.1.1.1 UAE: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.1.1.1.1 Overview
        • 11.1.1.1.2 UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.1.1.3 UAE: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.1.1.4 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.1.1.5 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.1.1.6 UAE: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.1.2 Saudi Arabia: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.1.1.2.1 Overview
        • 11.1.1.2.2 Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.1.2.3 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.1.2.4 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.1.2.5 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.1.2.6 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.1.3 South Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.1.1.3.1 Overview
        • 11.1.1.3.2 South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.1.3.3 South Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.1.3.4 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.1.3.5 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.1.3.6 South Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.1.4 Rest of the MEA: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.1.1.4.1 Overview
        • 11.1.1.4.2 Rest of the MEA: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.1.4.3 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.1.4.4 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.1.4.5 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.1.4.6 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)

12. MEA Pulmonary Arterial Hypertension Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Organic Developments
    • 12.2.1 Overview
  • 12.3 Inorganic Developments
    • 12.3.1 Overview

13. Company Profiles

  • 13.1 Johnson & Johnson
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Gilead Sciences Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Bayer AG
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Novartis AG
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 GSK Plc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Teva Pharmaceutical Industries Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Lupin Ltd
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Pfizer Inc
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms